BioSpace News Archive

Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, presented pivotal data from its largest cohort to date during a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois, and online.

NKGen Biotech, Inc. today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform at the 6th Annual Allogeneic Cell Therapies Summit to be held in Boston, MA, from June 10-12, 2024.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”) today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated, randomized, placebo-controlled Phase I/II trial to evaluate the efficacy, safety and tolerability of Allocetra™ following injection into patients with basal thumb joint (first carpometacarpal (CMC) joint) osteoarthritis.

Arcutis Biotherapeutics, Inc. today announced that Arcutis management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, taking place June 10-13, 2024.

Cue Biopharma, Inc. today announced that it will participate in two investor conferences this June, the Jefferies Global Healthcare Conference, to be held in New York, NY, June 4-6 and the Oppenheimer Novel Targets and Immunology Summit, to be held in New York, NY on June 24.

aTyr Pharma, Inc. announced that the Company will be changing its ticker symbol from “LIFE” to “ATYR.” Effective at the market open on June 5, 2024, the Company’s common stock will trade on the Nasdaq Capital Market under the new symbol “ATYR.”

23andMe Holding Co. presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31-June 4.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced today that the final results of the Phase IIa ALICE study evaluating iadademstat in combination with azacitidine in unfit patients with newly diagnosed acute myeloid leukemia (AML) were published online in The Lancet Hematology.

Rhythm Pharmaceuticals, Inc. today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m.

Elastin Biosciences today announced promising preclinical data from its in vivo mouse model studies.